▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1100 by analyst upside · 2026-11-13
PRAX
Praxis Precision Medicines, Inc.
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
+103.8%
implied upside to consensus target
Current Price $324.76
Consensus Target $661.75
Bull Target $1201.0
Bear Target $189.0
Analysts Covering 20
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
15
Hold
1
Sell
1
52-Week Low $160.11
52-Week High $392.7
YTD Return +13.4%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-12.82
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $160.11
52-Week High $392.7
Current Price $324.76
Bear Target $189.0
Bull Target $1201.0
● Now $324.76 ● Target $661.75
TRADING DATA
Avg Volume 455K
YTD Return +13.4%
Analyst Count 20
Consensus Buy
Upside to Target +103.8%
Last Updated 2026-11-13

ANALYST SUMMARY

Praxis Precision Medicines, Inc. (PRAX) is currently trading at $324.76 with a Wall Street consensus price target of $661.75, implying potential upside of 103.8% over the next 12 months. 20 analysts currently cover PRAX, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1201.0, while the most cautious has a target of $189.0.

PRAX operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 13.4% year-to-date and is currently trading near the upper end of its 52-week range of $160.11 – $392.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRAX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ● Initiated
Overweight 2026-10-16 43% win rate (7 calls)
UBS ● Initiated
Buy 2026-10-15 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-10-15 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-10-06 31% win rate (48 calls)
BTIG - Reiterated
Buy → Buy 2026-10-06 38% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-09-24 31% win rate (48 calls)
Needham reit
Buy → Buy 2026-09-24 20% win rate (5 calls)
Goldman Sachs - Reiterated
Buy → Buy 2026-08-21 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →